GT Biopharma Inc (GTBP) Stock Price, Quote & News

Company Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumo...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 919 4040

Website: www.gtbiopharma.com

Address:

315 Montgomery Street, 10th Floor, San Francisco, United States

YouVSYou Sep. 9 at 7:45 PM

$UCAR Interesting off $SUNE with $CYCN $BRTX $GTBP

0 · Reply

TwongStocks Sep. 8 at 8:09 PM

Today's reverse split results. 3 of 8 closed green today. Part 1 of 2: $AIXI 1 for 7 Previous close $0.4715, $3.3005 split-adjusted Today's high $3.45 (premarket) Today's close $3.26 🔴Down 1.23% $BRTX 1 for 20 Previous close $0.1480, $2.96 split-adjusted Today's high $3.23 Today's close $2.8028 🔴Down 5.31% $CTSO 1 for 20 Previous close $0.3501, $7.002 split-adjusted Today's high $7.44 Today's close $6.85 🔴Down 2.17% $GTBP 1 for 25 Previous close $0.2410, $6.025 split-adjusted Today's high $5.95 Today's close $5.2395 🔴Down 13.04%

0 · Reply

cninc Sep. 8 at 7:47 PM

$GTBP good to see mgnt F'ed things up again, unreal

0 · Reply

TwongStocks Sep. 8 at 11:34 AM

$AIXI $BRTX $CTSO $GTBP $LRHC Are among the nine NASDAQ stocks with reverse splits today. Full details in quoted post. Trading will resume at 9:00am ET with the RS in effect.

0 · Reply

TwongStocks Sep. 4 at 8:09 PM

Nine NASDAQ stocks with reverse splits on Tuesday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am Tuesday morning. I'll have to split this into two parts. Part 1 of 2: $AIXI 1 for 7. They do not have any recent SEC filings that confirm the current number of ADS outstanding. Unable to provide estimated post-RS share count without up to date data. $BRTX 1 for 20. Will reduce outstanding shares from approx 27.62m to approx 1.38m. $CTSO 1 for 20. Will reduce outstanding shares from approx 63.02m to approx 3.15m. $GTBP 1 for 25. Will reduce outstanding shares from approx 45.11m to approx 1.80m. $LRHC 1 for 6. Will reduce outstanding shares from approx 3.4m to approx 569k.

0 · Reply

TwongStocks Sep. 3 at 7:29 PM

$GTBP Equity Corporate Actions Alert #2026 - 644 Information Regarding the Reverse Stock Split and CUSIP Number Change for GT Biopharma, Inc. (GTBP) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-644 GT Biopharma, Inc. (GTBP) will effect a one-for-twenty five (1-25) reverse split of its Common Stock. The reverse stock split will become effective on Tuesday, September 8, 2026 . In conjunction with the reverse split, the CUSIP number will change to 36254L407.

1 · Reply

focafoca99 Sep. 3 at 6:04 PM

$GTBP new reverse split on Sep 8, really bad news... https://www.rapidticker.com/news/gtbp-information-regarding-the-reverse-stock-aa72a0

0 · Reply

brennan_lucas999 Aug. 26 at 4:21 PM

$GTBP

0 · Reply

calderinho Aug. 26 at 4:15 PM

$GTBP

0 · Reply

masonRhiiine Aug. 26 at 4:13 PM

$GTBP

0 · Reply

GT Biopharma trading halted, news pending

Aug 17, 2026, 8:00 AM EDT - 23 days ago

GT Biopharma Slides: Corporate presentation

Aug 14, 2026, 8:00 AM EDT - 26 days ago

GT Biopharma Reports Second Quarter 2026 Financial Results

Aug 14, 2026, 7:00 AM EDT - 26 days ago

GT Biopharma Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 26 days ago

GT Biopharma Earnings release: Q2 2026

Jul 2, 2026, 8:00 AM EDT - 2 months ago

GT Biopharma Proxy statement: Proxy filing

Jun 18, 2026, 8:00 AM EDT - 2 months ago

GT Biopharma Proxy statement: Proxy filing

Jun 8, 2026, 9:01 AM EDT - 3 months ago

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

Jun 1, 2026, 8:00 AM EDT - 3 months ago

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

May 15, 2026, 8:00 AM EDT - 3 months ago

GT Biopharma Reports First Quarter 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 3 months ago

GT Biopharma Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

GT Biopharma Earnings release: Q1 2026

2026-05-14T14:05:26.000Z - 3 months ago

GT Biopharma doses first patient in GTB-5550 trial

May 14, 2026, 8:30 AM EDT - 3 months ago

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors

2026-04-30T21:13:17.000Z - 4 months ago

GT Biopharma files to sell 9.72M shares of common stock for holders

Apr 30, 2026, 8:00 AM EDT - 4 months ago

GT Biopharma Registration statement: Registration filing

Apr 16, 2026, 2:00 PM EDT - 4 months ago

GT Biopharma Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Mar 9, 2026, 7:00 AM EDT - 6 months ago

GT Biopharma Slides: Corporate presentation

2026-03-03T13:31:45.000Z - 6 months ago

GT Biopharma price target lowered to $3 from $8 at Roth Capital

2026-03-02T21:36:20.000Z - 6 months ago

GT Biopharma price target lowered to $3 from $8 at Roth Capital

2026-03-02T12:12:33.000Z - 6 months ago

GT Biopharma expects cash to fund operations through Q4 2026

Mar 2, 2026, 7:00 AM EST - 6 months ago

GT Biopharma Reports Full Year 2025 Financial Results

Mar 2, 2026, 7:00 AM EST - 6 months ago

GT Biopharma Earnings release: Q4 2025

Mar 2, 2026, 7:00 AM EST - 6 months ago

GT Biopharma Annual report: Q4 2025

Feb 17, 2026, 7:30 AM EST - 6 months ago

GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference

2026-02-03T13:35:12.000Z - 7 months ago

GT Biopharma announces FDA clearance of IND application for GTB-5550

Feb 3, 2026, 8:30 AM EST - 7 months ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3

Jan 21, 2026, 7:00 AM EST - 7 months ago

GT Biopharma Registration statement: Registration Filing

2026-01-15T13:36:22.000Z - 7 months ago

GT Biopharma submits IND application to U.S. FDA for GTB-5550 TriKE

Jan 15, 2026, 8:30 AM EST - 7 months ago

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

Dec 19, 2025, 7:44 AM EST - 8 months ago

Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030

Nov 19, 2025, 8:00 AM EST - 9 months ago

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

2025-11-17T13:10:48.000Z - 9 months ago

GT Biopharma price target lowered to $8 from $11 at Roth Capital

2025-11-14T14:05:16.000Z - 9 months ago

GT Biopharma reports Q3 net loss $3.1M vs $3.4M last year

Nov 14, 2025, 9:00 AM EST - 9 months ago

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 14, 2025, 9:00 AM EST - 9 months ago

GT Biopharma Quarterly report: Q3 2025

Nov 14, 2025, 9:00 AM EST - 9 months ago

GT Biopharma Earnings release: Q3 2025

2025-10-24T20:20:16.000Z - 10 months ago

GT Biopharma files to sell 14.59M shares of common stock for holders

Oct 24, 2025, 8:00 AM EDT - 10 months ago

GT Biopharma Registration statement: Registration Filing

2025-10-08T13:10:29.000Z - 11 months ago

GT Biopharma provides enrollment update on GTB-3650 Phase 1 Trial

Sep 5, 2025, 7:00 AM EDT - 1 year ago

GT Biopharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:05 PM EDT - 1 year ago

GT Biopharma Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 7:00 AM EDT - 1 year ago

GT Biopharma Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

GT Biopharma Quarterly report: Q2 2025

2025-08-11T11:21:57.000Z - 1 year ago

GT Biopharma advances into cohort 3 of GTB-3650 Phase 1 trial

Aug 11, 2025, 7:00 AM EDT - 1 year ago

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

Jun 27, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Registration statement: Registration Filing

2025-06-13T13:10:35.000Z - 1 year ago

GT Biopharma appoints Mun-Gavin to board of directors

Jun 13, 2025, 9:00 AM EDT - 1 year ago

GT Biopharma Appoints New Member to its Board of Directors

2025-06-11T21:40:29.000Z - 1 year ago

GT Biopharma files to sell 120.55M shares of common stock for holders

Jun 11, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Registration statement: Registration Filing

Jun 11, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Proxy statement: Proxy Filing

Jun 11, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Proxy statement: Proxy Filing

May 30, 2025, 8:00 AM EDT - 1 year ago

GT Biopharma Proxy statement: Proxy Filing

2025-05-19T13:10:50.000Z - 1 year ago

GT Biopharma advances GTB-3650 Phase 1 trial to Cohort 2

May 19, 2025, 9:00 AM EDT - 1 year ago

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

May 15, 2025, 4:00 PM EDT - 1 year ago

GT Biopharma Quarterly report: Q1 2025

2025-05-15T13:16:23.000Z - 1 year ago

GT Biopharma appoints Andrew Ritter to board of directors

May 15, 2025, 6:00 AM EDT - 1 year ago

GT Biopharma Slides: Corporate Presentation

2025-05-14T11:32:30.000Z - 1 year ago

GT Biopharma appoints Kramer to board of directors

2025-03-06T22:25:27.000Z - 1 year ago

GT Biopharma files to sell 625,283 shares of common stock for holders

Mar 6, 2025, 7:00 AM EST - 1 year ago

GT Biopharma Registration statement: Registration Filing

Feb 25, 2025, 2:00 PM EST - 1 year ago

GT Biopharma Announces Exercise of Warrants

Feb 21, 2025, 3:00 PM EST - 1 year ago

GT Biopharma Annual report: Q4 2024

Feb 7, 2025, 7:00 AM EST - 1 year ago

GT Biopharma Registration statement: Registration Filing

Jan 27, 2025, 7:00 AM EST - 1 year ago

GT Biopharma Registration statement: Registration Filing

Dec 23, 2024, 7:00 AM EST - 1 year ago

GT Biopharma Registration statement: Registration Filing

Nov 19, 2024, 7:00 AM EST - 1 year ago

GT Biopharma Slides: Corporate Presentation

Nov 14, 2024, 4:00 PM EST - 1 year ago

GT Biopharma Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 7:00 AM EST - 1 year ago

GT Biopharma Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

GT Biopharma Earnings release: Q3 2024

Sep 26, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Sep 24, 2024, 9:15 AM EDT - 1 year ago

GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GT Biopharma Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GT Biopharma Earnings release: Q2 2024

Jun 27, 2024, 9:15 AM EDT - 2 years ago

GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

Jun 27, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Registration statement: Registration Filing

Jun 20, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Registration statement: Registration Filing

Jun 17, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

May 21, 2024, 9:15 AM EDT - 2 years ago

GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 20, 2024, 10:43 AM EDT - 2 years ago

What made GT Biopharma stock more than double on Monday?

May 15, 2024, 5:00 PM EDT - 2 years ago

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 15, 2024, 7:00 AM EDT - 2 years ago

GT Biopharma Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

GT Biopharma Earnings release: Q1 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

Mar 26, 2024, 5:00 PM EDT - 2 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 26, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Annual report: Q4 2023

Mar 26, 2024, 8:00 AM EDT - 2 years ago

GT Biopharma Earnings release: Q4 2023

Feb 1, 2024, 11:00 AM EST - 2 years ago

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

Dec 6, 2023, 9:30 AM EST - 2 years ago

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

Dec 4, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

Nov 6, 2023, 9:30 AM EST - 2 years ago

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nov 6, 2023, 7:00 AM EST - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

Nov 6, 2023, 7:00 AM EST - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

Nov 6, 2023, 7:00 AM EST - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

Nov 1, 2023, 9:00 AM EDT - 2 years ago

GT Biopharma Reports Third Quarter 2023 Financial Results

Nov 1, 2023, 8:00 AM EDT - 2 years ago

GT Biopharma Quarterly report: Q3 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

GT Biopharma Earnings release: Q3 2023

Oct 27, 2023, 8:00 AM EDT - 2 years ago

GT Biopharma Proxy statement: Proxy Filing

Aug 7, 2023, 9:00 AM EDT - 3 years ago

GT Biopharma Reports Second Quarter 2023 Financial Results

Aug 7, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Quarterly report: Q2 2023

Aug 7, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Earnings release: Q2 2023

Aug 3, 2023, 1:25 PM EDT - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

May 15, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 15, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Quarterly report: Q1 2023

May 15, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Earnings release: Q1 2023

May 5, 2023, 8:00 AM EDT - 3 years ago

GT Biopharma Proxy statement: Proxy Filing

May 5, 2023, 8:00 AM EDT - 3 years ago

GT Biopharma Proxy statement: Proxy Filing

May 4, 2023, 9:05 AM EDT - 3 years ago

GT Biopharma Names Charles J. Casamento to the Board of Directors

May 1, 2023, 8:00 AM EDT - 3 years ago

GT Biopharma Proxy statement: Proxy Filing

Mar 30, 2023, 5:00 PM EDT - 3 years ago

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Mar 30, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Annual report: Q4 2022

Mar 30, 2023, 7:00 AM EDT - 3 years ago

GT Biopharma Earnings release: Q4 2022

Feb 24, 2023, 9:00 AM EST - 3 years ago

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

Feb 2, 2023, 9:46 AM EST - 3 years ago

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

Dec 30, 2022, 8:00 AM EST - 3 years ago

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

Dec 14, 2022, 7:30 AM EST - 3 years ago

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Dec 12, 2022, 7:30 AM EST - 3 years ago

GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022

Nov 10, 2022, 3:15 PM EST - 3 years ago

GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Nov 3, 2022, 9:00 AM EDT - 3 years ago

GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting

Oct 31, 2022, 5:15 PM EDT - 3 years ago

GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update

Oct 31, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Quarterly report: Q3 2022

Oct 31, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Earnings release: Q3 2022

Oct 25, 2022, 2:44 PM EDT - 3 years ago

GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST

Oct 13, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Registration statement: Registration Filing

Oct 6, 2022, 8:18 AM EDT - 3 years ago

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

Oct 4, 2022, 4:10 PM EDT - 3 years ago

GT Biopharma Announces Adjournment of Special Shareholders Meeting

Oct 4, 2022, 8:00 AM EDT - 3 years ago

GT Biopharma Proxy statement: Proxy Filing

Sep 12, 2022, 9:34 AM EDT - 3 years ago

GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies

Sep 8, 2022, 7:30 AM EDT - 4 years ago

GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September

Aug 30, 2022, 6:00 PM EDT - 4 years ago

GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650

Aug 17, 2022, 8:00 AM EDT - 4 years ago

GT Biopharma Proxy statement: Proxy Filing

Aug 11, 2022, 9:35 AM EDT - 4 years ago

GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

YouVSYou Sep. 9 at 7:45 PM

$UCAR Interesting off $SUNE with $CYCN $BRTX $GTBP

0 · Reply

TwongStocks Sep. 8 at 8:09 PM

0 · Reply

cninc Sep. 8 at 7:47 PM

$GTBP good to see mgnt F'ed things up again, unreal

0 · Reply

TwongStocks Sep. 8 at 11:34 AM

$AIXI $BRTX $CTSO $GTBP $LRHC Are among the nine NASDAQ stocks with reverse splits today. Full details in quoted post. Trading will resume at 9:00am ET with the RS in effect.

0 · Reply

TwongStocks Sep. 4 at 8:09 PM

0 · Reply

TwongStocks Sep. 3 at 7:29 PM

1 · Reply

focafoca99 Sep. 3 at 6:04 PM

$GTBP new reverse split on Sep 8, really bad news... https://www.rapidticker.com/news/gtbp-information-regarding-the-reverse-stock-aa72a0

0 · Reply

brennan_lucas999 Aug. 26 at 4:21 PM

$GTBP

0 · Reply

calderinho Aug. 26 at 4:15 PM

$GTBP

0 · Reply

masonRhiiine Aug. 26 at 4:13 PM

$GTBP

0 · Reply

stocks_2watch Aug. 26 at 3:41 PM

$GTBP , GT Biopharma's Executive Chairman and CEO Michael Breen and Consulting Senior Medical Director Jeffrey S. Miller, M.D. have an Upcoming Webinar. sign up here for the webinar: https://globalonemedia.zoom.us/webinar/register/WN_V170bfBHSNSOxzJRsvgvlA#/registration

0 · Reply